What this means
This trial is looking at whether changing treatment based on frailty helps older patients with multiple myeloma. It has not reported results yet, so we do not know if it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 65 and over
- Where
- 1 site
The science
- Registered title
- Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
- Trial ID
- NCT06099912 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Multiple Myeloma, Frailty
- Sponsor
- FengYan Jin
- Ages
- 65 Years to no maximum
- Dates
- First posted Oct 25, 2023 · updated Feb 12, 2026
Registry summary
Frailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability. We designed a multi-center prospective study (DynaFiT) based on our real-life practice to evaluate the feasibility and benefits of a dynamic frailty-tailored therapy in elderly patients with different fitness/frailty statuses.
Since Dara-based treatment have recently become the new standard regimens, in this amendment of the study, daratumumab added to VRd is recommended as induction therapy regimen.
Sites (1)
- The First Hospital of Jilin University, Changchun, Jilin, China